Nitric oxide by SaNOtize Research and Development for Warts: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nitric oxide overview

Nitric oxide (FabiSpray) is a free radical which acts as a bronchodilator agent. It is formulated as spray for inhalational route of administation. FabiSpray is indicated for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.

Nitric oxide is under development for the prevention and treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human papillomavirus verrucae plantaris(plantar warts) and oropharyngeal candidiasis. The drug candidate is formulated as solution and administered as gargle, nasal spray or as a nasopharyngeal flush. It is being developed based on nitric oxide releasing solution (NORS) platform technology.

SaNOtize Research and Development overview

SaNOtize Research and Development (Sanotize) is a biotechnology company focusing on nitric oxide releasing solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Sanotize is headquartered in Vancouver, British Columbia, Canada.

For a complete picture of Nitric oxide’s drug-specific PTSR and LoA scores, buy the report here.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.